Achillion Pharmaceuticals, Inc. announced an operational restructuring plan that aims to focus the organization on advancing Achillion's existing clinical and late-stage preclinical factor D inhibitors and reduce expenses to maintain its strong balance sheet. The restructuring will reduce the company's workforce by approximately 20% to approximately 70 employees.

In addition, the company announced that Joseph Truitt has been promoted to President and Chief Operating Officer, continuing to report to Chief Executive Officer, Milind Deshpande, Ph.D.